Strategic partnerships Quidel has a history of strategic collaborations with Beckman Coulter and Global Lyme Alliance, indicating openness to co-development, distribution partnerships, and joint marketing initiatives that could be leveraged for joint product launches or integrated diagnostic solutions.

Acquisition-driven growth The 2021 Mesa Biotech acquisition suggests a track record of expanding capabilities through acquisitions, signaling potential for integrating complementary molecular diagnostics or expanding geographic and customer reach to accelerate sales.

MDx platform momentum The Savanna MDx platform launch points to a focus on multiplex diagnostic solutions; opportunities exist to position complementary assays, software analytics, or bundled service offerings to healthcare providers seeking end-to-end diagnostic workflows.

Regulatory and quality emphasis Adherence to ISO/IEC 27701 and other standards indicates a maturity in data privacy and quality management, making the company a suitable partner for enterprise or high-security healthcare accounts requiring compliant solutions.

Market risk signals Recent securities-related litigation exposure may necessitate targeted messaging to reassure risk-averse buyers and emphasize robust governance, support, and continuity offerings to protect customer and channel partner interests.